SPV-400
| Clinical data | |
|---|---|
| Other names | SPV400 |
| Routes of administration | Parenteral |
| Drug class | Tropomyosin receptor kinase B (TrkB) agonist |
SPV-400 is a tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of neurological disorders. It is taken parenterally. The preclinical pharmacokinetics of SPV-400 have been studied and described. The drug is under development by Spave Science. As of August 2025, it is in the preclinical research stage of development for neurological disorders. The chemical structure of SPV-400 does not yet appear to have been disclosed.
See also
References
- 1 2 3 4 5 6 7 "SPV 400". AdisInsight. 1 August 2025. Retrieved 10 June 2026.
- 1 2 3 "Delving into the Latest Updates on SPV-400 with Synapse". Synapse. 11 March 2026. Retrieved 10 June 2026.
- 1 2 Choi EJ, Renger J, Iuvone PM (8 April 2025). "Absorption, Distribution, Metabolism, And Excretion (ADME) And Pharmacokinetic (PK) Properties of SPV-400, a Novel Tropomyosin Kinase Receptor B (TrkB) Activator (P9-2.002)". Neurology. 104 (7_Supplement_1) 2910. doi:10.1212/WNL.0000000000210660. ISSN 0028-3878.
External links
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |